secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001437749-23-030228
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech receives Nasdaq extension to April 29, 2024 to meet $1 bid price rule
--------------------------------------------------------------------------------

- Initial 180-day compliance period expired Nov 1, 2023; second period granted until April 29, 2024.
- Company must close at $1.00+ for 10 consecutive business days to regain compliance.
- If using reverse stock split, it must be completed by April 19, 2024 (10 business days before deadline).
- Failure by April 29 may lead to delisting; company can appeal to Nasdaq Hearings Panel.
- No immediate effect on trading; shares continue on Nasdaq under symbol MBRX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923030228/0001437749-23-030228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923030228/mbrx20231102c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer